Literature DB >> 12497608

Early-onset schizophrenia and dopamine-related gene polymorphism.

Yasuhide Iwata1, Hideo Matsumoto, Yoshio Minabe, Naoko Osada, Kazuhiko Nakamura, Takahiro Sekizawa, Katsuaki Suzuki, Yoshimoto Sekine, Nori Takei, Norio Mori.   

Abstract

Schizophrenic patients with an onset before age 16 years (early-onset schizophrenia, EOS) would be a rare but attractive subpopulation for genetic studies. This study explored the relationship between the polymorphism of four dopamine-regulating-enzymes (tyrosine hydroxylase, dopamine-beta-hydroxylase, catechol-O-methyltransferase, monoamine oxidase-A) genes, four dopamine-receptors (dopamine D1, D2, D3, D4 receptors) genes and susceptibility to EOS in a Japanese sample. Subjects comprised 51 Japanese patients who met DSM-IV criteria for schizophrenia with an onset before age 16 (by age 15) and 148 Japanese healthy controls. DNA was extracted from whole blood and genotyping was carried out by PCR-RELP using each restriction endonuclease. No significant difference was found in the allele frequencies or genotype distributions of any of the eight genes examined between EOS and the control groups. We did not find the relationship between the polymorphism of eight dopamine-related genes and susceptibility to EOS in a Japanese sample. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12497608     DOI: 10.1002/ajmg.b.10759

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  9 in total

Review 1.  Meta-analysis shows association between the tryptophan hydroxylase (TPH) gene and schizophrenia.

Authors:  Dawei Li; Lin He
Journal:  Hum Genet       Date:  2006-06-02       Impact factor: 4.132

2.  Variable number of tandem repeat polymorphisms of DRD4: re-evaluation of selection hypothesis and analysis of association with schizophrenia.

Authors:  Eiji Hattori; Mizuho Nakajima; Kazuo Yamada; Yoshimi Iwayama; Tomoko Toyota; Naruya Saitou; Takeo Yoshikawa
Journal:  Eur J Hum Genet       Date:  2008-12-17       Impact factor: 4.246

3.  MAOA Variants and Genetic Susceptibility to Major Psychiatric Disorders.

Authors:  Zichao Liu; Liang Huang; Xiong-Jian Luo; Lichuan Wu; Ming Li
Journal:  Mol Neurobiol       Date:  2015-07-31       Impact factor: 5.590

Review 4.  The Role of a Catechol-O-Methyltransferase (COMT) Val158Met Genetic Polymorphism in Schizophrenia: A Systematic Review and Updated Meta-analysis on 32,816 Subjects.

Authors:  Thelma Beatriz González-Castro; Yazmin Hernández-Díaz; Isela Esther Juárez-Rojop; María Lilia López-Narváez; Carlos Alfonso Tovilla-Zárate; Ana Fresan
Journal:  Neuromolecular Med       Date:  2016-03-28       Impact factor: 3.843

Review 5.  Gene-sex interactions in schizophrenia: focus on dopamine neurotransmission.

Authors:  Sean C Godar; Marco Bortolato
Journal:  Front Behav Neurosci       Date:  2014-03-06       Impact factor: 3.558

6.  Associations between dopamine D2 receptor gene polymorphisms and schizophrenia risk: a PRISMA compliant meta-analysis.

Authors:  Hairong He; Huanhuan Wu; Lihong Yang; Fan Gao; Yajuan Fan; Junqin Feng; Xiancang Ma
Journal:  Neuropsychiatr Dis Treat       Date:  2016-12-09       Impact factor: 2.570

7.  Association of dopamine D1 receptor gene polymorphism with schizophrenia: a meta-analysis.

Authors:  Yuqing Pan; Jun Yao; Baojie Wang
Journal:  Neuropsychiatr Dis Treat       Date:  2014-06-20       Impact factor: 2.570

8.  No association between dopamine D3 receptor gene Ser9Gly polymorphism (rs6280) and risk of schizophrenia: an updated meta-analysis.

Authors:  Xing-Ling Qi; Jin-Feng Xuan; Jia-Xin Xing; Bao-Jie Wang; Jun Yao
Journal:  Neuropsychiatr Dis Treat       Date:  2017-11-23       Impact factor: 2.570

9.  Association of rs4680 COMT, rs6280 DRD3, and rs7322347 5HT2A With Clinical Features of Youth-Onset Schizophrenia.

Authors:  Anna Morozova; Yana Zorkina; Konstantin Pavlov; Olga Pavlova; Zinaida Storozheva; Eugene Zubkov; Natalia Zakharova; Olga Karpenko; Alexander Reznik; Vladimir Chekhonin; Georgiy Kostyuk
Journal:  Front Psychiatry       Date:  2019-11-12       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.